InsiderTrades

Form 4 for PCSA Processa Pharmaceuticals, Inc.

Accepted 2024-04-12 00:00:00 ET · period of report 2024-01-01 · accession 0000897069-24-000919 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-04-12 2024-01-01 PCSA Bigora Sian Chief Development Off M - OptEx — +1,675 21.8K +8% —
D 2024-04-12 2024-01-01 PCSA Bigora Sian Chief Development Off F - Tax $2.79 -368 21.5K -2% -$1,027
D 2024-04-12 2024-01-01 PCSA Bigora Sian Chief Development Off M - OptEx $0.00 -1,675 22.1K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-01 M A 1,675 — 21,826 D — — (F1) Distribution of vested restricted shares. (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
2 Common Common Stock 2024-01-01 F D 368 $2.79 21,458 D — — (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
3 Derivative Restricted Stock Units 2024-01-01 M D 1,675 $0.00 22,139 D $0.00 · — to — 1,675 Common Stock (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. (F1) Distribution of vested restricted shares.